Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Clinical and Developmental Immunology
Volume 2010, Article ID 504979, 9 pages
http://dx.doi.org/10.1155/2010/504979
Clinical Study

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

1Immunotherapy Unit, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), 47014 Meldola, Italy
2Unit of Biostatistics and Clinical Trials, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), 47014 Meldola, Italy
3Blood Transfusion Unit, Morgagni-Pierantoni Hospital, 47100 Forlì, Italy
4Thoracic Surgery Unit, Morgagni-Pierantoni Hospital, 47100 Forlì, Italy
5Advanced Oncological Surgery Unit, Morgagni-Pierantoni Hospital, 47100 Forlì, Italy

Received 22 June 2010; Accepted 13 August 2010

Academic Editor: Bernhard Fleischer

Copyright © 2010 Laura Ridolfi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Baade and M. Coory, “Trends in melanoma mortality in Australia: 1950–2002 and their implications for melanoma control,” Australian and New Zealand Journal of Public Health, vol. 29, no. 4, pp. 383–386, 2005. View at Google Scholar · View at Scopus
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  3. H. Tsao, M. Atkins, and A. Sober, “Management of cutaneous melanoma,” New England Journal of Medicine, vol. 351, no. 10, pp. 998–1012, 2004. View at Google Scholar
  4. T. Crosby, R. Fish, B. Coles, and M. D. Mason, “Systemic treatments for metastatic cutaneous melanoma,” Cochrane Database of Systematic Reviews, no. 2, p. CD001215, 2000. View at Google Scholar · View at Scopus
  5. M. L. Lee, K. Tomsu, and K. B. Von Eschen, “Duration of survival for disseminated malignant melanoma: results of a meta-analysis,” Melanoma Research, vol. 10, no. 1, pp. 81–92, 2000. View at Google Scholar · View at Scopus
  6. E. Bajetta, M. Del Vecchio, C. Bernard-Marty et al., “Metastatic melanoma: chemotherapy,” Seminars in Oncology, vol. 29, no. 5, pp. 427–445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. T. Flaherty, “Chemotherapy and targeted therapy combinations in advanced melanoma,” Clinical Cancer Research, vol. 12, no. 7, pp. 2366s–2370s, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. B. Chapman, L. H. Einhorn, M. L. Meyers et al., “Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2745–2751, 1999. View at Google Scholar · View at Scopus
  9. D. Schadendorf, S. Ugurel, B. Schuler-Thurner et al., “Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG,” Annals of Oncology, vol. 17, no. 4, pp. 563–570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Huncharek, J. F. Caubet, and R. McGarry, “Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials,” Melanoma Research, vol. 11, no. 1, pp. 75–81, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Keilholz and M. E. Gore, “Biochemotherapy for advanced melanoma,” Seminars in Oncology, vol. 29, no. 5, pp. 456–461, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Pardoll, “Does the immune system see tumors as foreign or self?” Annual Review of Immunology, vol. 21, pp. 807–839, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. G. P. Dunn, L. J. Old, and R. D. Schreiber, “The immunobiology of cancer immunosurveillance and immunoediting,” Immunity, vol. 21, no. 2, pp. 137–148, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. B. Swann and M. J. Smyth, “Immune surveillance of tumors,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1137–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Ferrone and T. L. Whiteside, “Tumor Microenvironment and Immune Escape,” Surgical Oncology Clinics of North America, vol. 16, no. 4, pp. 755–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. L. Whiteside, “The tumor microenvironment and its role in promoting tumor growth,” Oncogene, vol. 27, no. 45, pp. 5904–5912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Lanzavecchia and F. Sallusto, “Regulation of T cell immunity by dendritic cells,” Cell, vol. 106, no. 3, pp. 263–266, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Shurin, “Dendritic cells presenting tumor antigen,” Cancer Immunology Immunotherapy, vol. 43, no. 3, pp. 158–164, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Engell-Noerregaard, T. H. Hansen, M. H. Andersen, P. Thor Straten, and I. M. Svane, “Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters,” Cancer Immunology, Immunotherapy, vol. 58, no. 1, pp. 1–14, 2009. View at Publisher · View at Google Scholar
  22. S. J. Antonia, N. Mirza, I. Fricke et al., “Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer,” Clinical Cancer Research, vol. 12, no. 3 part I, pp. 878–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Inogès, M. Rodrìguez-Calvillo, N. Zabalegui et al., “Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma,” Journal of the National Cancer Institute, vol. 98, no. 18, pp. 1292–1301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. G. Gribben, D. P. Ryan, R. Boyajian et al., “Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy,” Clinical Cancer Research, vol. 11, no. 12, pp. 4430–4436, 2005. View at Publisher · View at Google Scholar
  25. J. Schlom, P. M. Arlen, and J. L. Gulley, “Cancer vaccines: moving beyond current paradigms,” Clinical Cancer Research, vol. 13, no. 13, pp. 3776–3782, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Ramakrishnan, S. Antonia, and D. I. Gabrilovich, “Combined modality immunotherapy and chemotherapy: a new perspective,” Cancer Immunology, Immunotherapy, vol. 57, no. 10, pp. 1523–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Ridolfi, M. Petrini, L. Fiammenghi et al., “Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients,” Journal of Translational Medicine, vol. 4, article 36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Hoos, G. Parmiani, K. Hege et al., “A clinical development paradigm for cancer vaccines and related biologics,” Journal of Immunotherapy, vol. 30, no. 1, pp. 1–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Marubini and M. G. Valsecchi, “Analysing survival data from clinical trials and observational studies,” in Statistics in Practice, V. Barnett, Ed., John Wiley & Sons, Chichester, UK, 1995. View at Google Scholar
  30. M. R. Middleton, J. J. Grob, N. Aaronson et al., “Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 158–166, 2000. View at Google Scholar · View at Scopus
  31. M. B. Atkins, “The treatment of metastatic melanoma with chemotherapy and biologics,” Current Opinion in Oncology, vol. 9, no. 2, pp. 205–213, 1997. View at Google Scholar · View at Scopus
  32. S. S. Legha, S. Ring, N. Papadopoulos, M. Raber, and R. S. Benjamin, “A phase II trial of taxol in metastatic melanoma,” Cancer, vol. 65, no. 11, pp. 2478–2481, 1990. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Y. Bedikian, G. R. Weiss, S. S. Legha et al., “Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy,” Journal of Clinical Oncology, vol. 13, no. 12, pp. 2895–2899, 1995. View at Google Scholar · View at Scopus
  34. M. F. Avril, S. Aamdal, J. J. Grob et al., “Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study,” Journal of Clinical Oncology, vol. 22, no. 6, pp. 1118–1125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. A. C. Buzaid, “Cisplatin, vinblastine, and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial,” Proceedings of the American Society of Clinical Oncology, vol. 12, no. 389, 1993. View at Google Scholar
  36. M. B. Atkins, K. R. O'Boyle, J. A. Sosman et al., “Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma,” Journal of Clinical Oncology, vol. 12, no. 8, pp. 1553–1560, 1994. View at Google Scholar · View at Scopus
  37. J. Atzpodien, E. Lopez Hänninen, H. Kirchner et al., “Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen,” European Journal of Cancer A, vol. 31, no. 6, pp. 876–881, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Gibbs, A. Iannucci, M. Becker et al., “A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma,” Melanoma Research, vol. 10, no. 2, pp. 171–179, 2000. View at Google Scholar · View at Scopus
  39. S. S. Legha, S. Ring, A. Bedikian et al., “Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-,” Annals of Oncology, vol. 7, no. 8, pp. 827–835, 1996. View at Google Scholar · View at Scopus
  40. V. Chiarion-Sileni, P. Del Bianco, G. L. de Salvo et al., “Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients,” European Journal of Cancer, vol. 39, no. 11, pp. 1577–1585, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber et al., “Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 968–975, 1999. View at Google Scholar · View at Scopus
  42. N. J. Ives, R. L. Stowe, P. Lorigan, and K. Wheatley, “Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5426–5434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Ridolfi, V. Chiarion-Sileni, M. Guida et al., “Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1600–1607, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. J. S. Weber, “The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies,” Melanoma Research, vol. 16, no. 5, pp. 379–383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Ridolfi and R. Ridolfi, “Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010),” Expert Review of Dermatology, vol. 4, no. 3, pp. 199–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. J. O'Day, O. Hamid, and W. J. Urba, “Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies,” Cancer, vol. 110, no. 12, pp. 2614–2627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Apetoh, F. Ghiringhelli, A. Tesniere et al., “Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy,” Nature Medicine, vol. 13, no. 9, pp. 1050–1059, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Demaria, B. Ng, M. L. Devitt et al., “Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 862–870, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Demaria, N. Bhardwaj, W. H. McBride, and S. C. Formenti, “Combining radiotherapy and immunotherapy: a revived partnership,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 3, pp. 655–666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Ghiringhelli, N. Larmonier, E. Schmitt et al., “CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative,” European Journal of Immunology, vol. 34, no. 2, pp. 336–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. F. M. Venanzi, M. Petrini, L. Fiammenghi et al., “Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome,” Cancer Immunology, Immunotherapy, vol. 59, no. 1, pp. 27–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, “Immunological aspects of cancer chemotherapy,” Nature Reviews Immunology, vol. 8, no. 1, pp. 59–73, 2008. View at Publisher · View at Google Scholar · View at Scopus